CORE Diagnostics and CanCertain Healthcare have partnered to improve personalized cancer treatment, addressing anxiety and uncertainties faced by cancer patients and their families. The partnership addresses treatment choices, expenses, efficacy, and potential side effects, enabling oncologists to quickly devise effective treatment strategies for individual patients.

CanCertain Healthcare's CanCertain test provides crucial information about a patient's tumor's sensitivity or resistance to specific cancer drugs, enabling oncologists to make more informed treatment choices, saving time and reducing financial strain associated with ineffective treatments.

Dr Shivani Sharma, Vice President of Pathology Services & Lab Director, CORE Diagnostics said, “The CanCertain test is a game-changer in the field of oncology. It allows us to identify the most effective drugs for a patient’s unique tumor and consider their individual immunity and drug resistance. By doing so, we minimise the need for multiple rounds of different drugs, safeguard the patient’s immune system, and significantly improve the chances of successful cancer treatment.”

The collaboration focuses on empowering healthcare providers and oncologists, providing them with crucial information to prescribe effective treatments, thereby optimizing the patient's recovery path, rather than relying on direct patient interactions.

Dinesh Chauhan, CEO, CORE Diagnostics, comments, “CORE Diagnostics is proud to partner with CanCertain Healthcare to enhance the precision and effectiveness of cancer treatment. Our combined expertise will not only benefit patients but also healthcare providers who strive to deliver the best possible care.”